Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income
Reuters
Sep 26
Sunho Biologics Reports 178% Increase in Other Income for First Half of 2025, Driven by Higher Interest Income
Sunho Biologics Inc. released its Interim Report 2025, providing an update on its financial performance for the six months ended June 30, 2025. During the reporting period, the company recorded other income of RMB5.04 million, compared to RMB1.78 million for the same period in 2024, representing an increase of 178%. The increase was mainly attributed to higher interest income from financial institutions, which rose to RMB5.02 million from RMB1.74 million in the prior year period. Government grants received during the period totaled RMB17,000, down from RMB38,000 in the previous year. No significant events affecting business operations were reported after the end of the reporting period up to September 16, 2025. The company did not provide an outlook or guidance in the disclosed segments of the report.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunho Biologics Inc. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.